We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

CRISPR-Cas9 gene editing pioneer secures licence

Lighthouse | 07 May 2020

BerGenBio

NOK500m raised to drive bemcentinib progress

Lighthouse | 05 May 2020

MaxCyte

£25.1m ($31.0m) successully raised

Lighthouse | 05 May 2020

Nexstim

€2.3m rights issue to progress both NBS and NBT

Lighthouse | 04 May 2020

Hutchison China MediTech

AACR 2020: first surufatinib/PD-1 combo data

Update | 30 April 2020

BerGenBio

Bemcentinib fast-tracked into COVID-19 trial

Lighthouse | 30 April 2020

MaxCyte

FY19 results crown a breakthrough year

Lighthouse | 21 April 2020

Hutchison China MediTech

Weathering the COVID-19 storm

Update | 20 April 2020

Hutchison China MediTech

Laying the foundations for a new era

Outlook | 20 April 2020

Nexstim

Patient registry shows promising outcomes in MDD

Lighthouse | 20 April 2020
< 2 3 4 5 6 7 8 9 10 11 >
241 results found.